Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HAVCR2 | Q8TDQ0 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | AHR | P35869 | 1/20 | 0.31 |
| ▸ | PDE5A | O76074 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23029998 | 0.82 | PDE10A (0.34) | HAVCR2HPGDLMNATSHRPDE10A | |
| SCHEMBL23029946 | 0.78 | HAVCR2 (0.39) | HAVCR2HPGDLMNATSHRPDE10A | |
| SCHEMBL24857434 | 0.77 | HTR6 (0.32) | HAVCR2PDE10AHTR6SMN1; SMN2HSD17B10 | |
| SCHEMBL23029979 | 0.75 | HAVCR2 (0.37) | HAVCR2HPGDLMNATSHRPDE10A | |
| SCHEMBL23030300 | 0.63 | ALOX15 (0.33) | TSHR | |
| SCHEMBL16565475 | 0.63 | AHR (0.54) | HAVCR2HPGDPDE10ASMN1; SMN2HSD17B10 | |
| SCHEMBL31330001 | 0.60 | HPGD (0.36) | HAVCR2HPGDLMNATSHRPDE10A | |
| SCHEMBL31329841 | 0.60 | HAVCR2 (0.36) | HAVCR2HPGDLMNATSHRPDE10A | |
| SCHEMBL31329986 | 0.60 | HPGD (0.36) | HAVCR2HPGDLMNATSHRPDE10A | |
| SCHEMBL16439330 | 0.59 | EGLN2 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583870-B2 | Azaheteroaryl compound and application thereof | SHANGHAI BLUERAY BIOPHARMA CO., LTD. (CN) | 2026-03-24 | — | — | US | disclosed |
| US-20230002414-A1 | AZAHETEROARYL COMPOUND AND APPLICATION THEREOF | SHANGHAI BLUERAY BIOPHARMA CO., LTD. (CN) | 2023-01-05 | — | — | US | disclosed |
| US-20230002414-A1 | AZAHETEROARYL COMPOUND AND APPLICATION THEREOF | SHANGHAI BLUERAY BIOPHARMA CO., LTD. (CN) | 2023-01-05 | — | — | US | disclosed |
| EP-4019521-A1 | AZAHETEROARYL COMPOUND AND APPLICATION THEREOF | Blueray Therapeutics (Shanghai) Co., Ltd (CN) | 2022-06-29 | — | — | EP | disclosed |
| EP-4019521-A1 | AZAHETEROARYL COMPOUND AND APPLICATION THEREOF | Blueray Therapeutics (Shanghai) Co., Ltd (CN) | 2022-06-29 | — | — | EP | disclosed |
| WO-2021032004-A9 | AZAHETEROARYL COMPOUND AND APPLICATION THEREOF | 上海青煜医药科技有限公司 | 2021-03-25 | — | — | WO | disclosed |
| WO-2021032004-A1 | AZAHETEROARYL COMPOUND AND APPLICATION THEREOF | 上海青煜医药科技有限公司 | 2021-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002414-A1 | AZAHETEROARYL COMPOUND AND APPLICATION THEREOF | EZH2, EED, SUZ12 | HAVCR2 2990/4885HPGD 2809/4885LMNA 4362/4885 |
| US-12583870-B2 | Azaheteroaryl compound and application thereof | NR3C1, EED, EZH2 | HAVCR2 1076/4885HPGD 3579/4885LMNA 3329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.